SequelSEC

VYCOR MEDICAL INC VYCO

Surgical & Medical Instruments & Apparatus · CIK 0001424768 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.81M
Fiscal year ended 2026-06-30
Operating income
$48.22K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.71MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.05Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue0.5%2th
CapEx / revenue0.3%3th
Current ratio0.12x3th
Gross margin83.8%91th
Operating margin1.8%69th
SBC / revenue2.6%31th
Net margin-3.9%68th
FCF margin-1.0%61th
Revenue YoY growth17.2%61th

VYCOR MEDICAL INC (VYCO) reported revenue of $1.81M and net income of -$59.93K for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from VYCOR MEDICAL INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

VYCOR MEDICAL INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.81M
Cost of revenue$300.57K
Gross profit$1.51M
Operating income$48.22K
Net income-$59.93K
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$56.40K
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$1.40M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

VYCOR MEDICAL INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$158.91K
Total assets$813.17K
Current assets$635.88K
Total liabilities$5.06M
Current liabilities$4.93M
Total equity incl. NCI-$4.25M
Temporary (mezzanine) equityUnavailable
Inventory$190.51K
Accounts receivable$202.45K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$111.78K

Cash flow

VYCOR MEDICAL INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$61.38K
Capital expendituresUnavailable
Investing cash flow$876
Financing cash flow-$3.07K
Net change in cash$59.21K
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$58.62K

Derived

VYCOR MEDICAL INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin83.4%
Operating margin2.7%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.13x
Revenue YoY growth1.6%
Net margin-3.3%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VYCO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.